BRAF-activating mutations have been detected in nearly all craniopharyngiomas of the papillary subtype, with interesting implications for patients with suboptimal tumor control. Here we report that combined treatment with BRAF and MEK inhibitors resulted in major clinical benefit in the case of a patient with a BRAF V600E-mutant papillary craniopharyngioma rapidly progressing after surgery.

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma / Di Stefano, A. L.; Guyon, D.; Sejean, K.; Feuvret, L.; Villa, C.; Berzero, G.; Desforges Bullet, V.; Halimi, E.; Boulin, A.; Baussart, B.; Gaillard, S.. - In: NEURO-ONCOLOGY ADVANCES. - ISSN 2632-2498. - 2:1(2020). [10.1093/noajnl/vdaa141]

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma

Berzero G.;
2020-01-01

Abstract

BRAF-activating mutations have been detected in nearly all craniopharyngiomas of the papillary subtype, with interesting implications for patients with suboptimal tumor control. Here we report that combined treatment with BRAF and MEK inhibitors resulted in major clinical benefit in the case of a patient with a BRAF V600E-mutant papillary craniopharyngioma rapidly progressing after surgery.
2020
BRAF V600E mutation
anti-BRAF
anti-MEK
papillary craniopharyngioma
target therapy
File in questo prodotto:
File Dimensione Formato  
vdaa141.pdf

accesso aperto

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Creative commons
Dimensione 230.91 kB
Formato Adobe PDF
230.91 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/143121
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 1
social impact